度普利尤单抗与奥马珠单抗治疗伴哮喘的慢性鼻窦炎伴鼻息肉患者(EVEREST):多中心、随机、双盲、头对头4期试验
EVEREST是首个呼吸系统生物制剂头对头试验,在17个国家100家中心纳入360例重度未控制慢性鼻窦炎伴鼻息肉且合并哮喘的成人患者,随机接受皮下度普利尤单抗300 mg每2周或奥马珠单抗按体重和IgE分层每2周或4周,均联合糠酸莫米松鼻喷雾剂,疗程24周。主要终点为24周鼻息肉评分和UPSIT较基线变化,度普利尤单抗优于奥马珠单抗:鼻息肉评分最小二乘均值差-1.60(95%CI -1.96至-1.25,p<0.0001),UPSIT 8.0(6.3至9.7,p<0.0001)。两组治疗中出现的不良事件发生率分别为64%和67%,最常见为鼻咽炎、意外过量、头痛、上呼吸道感染和咳嗽,无死亡。
要点
- 在伴哮喘的重度CRSwNP患者中,度普利尤单抗300 mg皮下每2周较奥马珠单抗(按体重和IgE分层每2周或4周)在24周时鼻息肉评分改善多1.60分(95%CI -1.96至-1.25,p<0.0001)。
- 同一人群中,度普利尤单抗较奥马珠单抗在24周时UPSIT评分改善多8.0分(95%CI 6.3至9.7,p<0.0001)。
- 两组治疗中出现的不良事件发生率相似:度普利尤单抗组64%(115/179) vs 奥马珠单抗组67%(116/173),最常见为鼻咽炎、意外过量、头痛、上呼吸道感染和咳嗽,无死亡。
- 纳入标准包括鼻息肉评分≥5分(每侧鼻孔≥2分)、筛查前鼻塞和嗅觉丧失至少8周、医生诊断的哮喘,且FEV1≤85%预计值(原文排除标准之一为未满足支气管舒张前FEV1≤85%预计值)。
适用人群与场景
- 年龄≥18岁、重度未控制慢性鼻窦炎伴鼻息肉(鼻息肉评分≥5分且每侧鼻孔≥2分)、筛查前鼻塞和嗅觉丧失至少8周、医生诊断的哮喘。
- 研究在17个国家100家医院或临床中心进行,中心需具备耳鼻喉科、呼吸科、过敏科和免疫科实践,并拥有鼻内镜和心电图机。
诊断标准与关键阈值
- 鼻息肉评分≥5分(每侧鼻孔≥2分)。
- 筛查前鼻塞和嗅觉丧失症状持续至少8周。
- 医生诊断的哮喘。
- 支气管舒张前FEV1≤85%预计值(原文排除标准之一为未满足此条件)。
处置流程与药物剂量
- 度普利尤单抗300 mg皮下注射每2周一次,联合背景糠酸莫米松鼻喷雾剂,疗程24周。
- 奥马珠单抗按体重和IgE分层给药,每2周或4周一次,联合背景糠酸莫米松鼻喷雾剂,疗程24周。
研究设计与关键结果
- EVEREST为国际、随机、双盲、4期头对头试验,17个国家100家中心,纳入360例患者(度普利尤单抗组181例,奥马珠单抗组179例),主要终点为24周鼻息肉评分和UPSIT较基线变化。
- 24周时度普利尤单抗较奥马珠单抗鼻息肉评分最小二乘均值差为-1.60(95%CI -1.96至-1.25,p<0.0001),UPSIT最小二乘均值差为8.0(95%CI 6.3至9.7,p<0.0001)。
- 治疗中出现的不良事件:度普利尤单抗组115/179(64%) vs 奥马珠单抗组116/173(67%),最常见为鼻咽炎、意外过量、头痛、上呼吸道感染和咳嗽,无死亡。
证据类型、等级与局限
- 证据类型:多中心、随机、双盲、头对头4期试验(EVEREST,NCT04998604)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,这些发现支持度普利尤单抗在2型呼吸系统疾病患者中相对于活性生物制剂对照的疗效,并可能有助于临床实践中对CRSwNP合并哮喘患者进行更好的治疗靶向选择。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Chronic rhinosinusitis with nasal polyps (CRSwNP) is predominantly driven by type 2 inflammation. The biologics dupilumab and omalizumab, which target drivers and mediators of type 2 inflammation (interleukin [IL]-4/IL-13 signaling and immunoglobulin E [IgE], respectively), are efficacious in treating CRSwNP but direct comparisons are few. In EVEREST (EValuating trEatment RESponses of dupilumab versus omalizumab), the first head-to-head trial in respiratory biologics, we aimed to compare the efficacy and safety of dupilumab and omalizumab in patients with severe CRSwNP who had mild, moderate, or severe asthma.
METHODS: EVEREST was an international, randomised, double-blind, phase 4 trial, conducted at 100 hospitals or clinical centres in 17 countries. Sites were selected with otolaryngology, pneumologist, allergist, and immunologist practices; needed to have previously conducted double-blind studies; and were required have nasal endoscopy and electrocardiogram machines. Eligible patients aged 18 years or older with severe uncontrolled CRSwNP (with a nasal polyp score of 5 or more [and ≥2 for each nostril]), symptoms of nasal congestion and loss of smell for at least 8 weeks before screening, and physician-diagnosed asthma. Patients were randomly assigned (1:1) to subcutaneous dupilumab 300 mg every 2 weeks or omalizumab weight-tiered and IgE-tiered dosing every 2 weeks or 4 weeks for 24 weeks, with background mometasone furoate nasal spray. Patients and investigators were masked to the study drugs. Primary endpoints were change from baseline in endoscopic nasal polyp score and University of Pennsylvania Smell Identification Test (UPSIT) at 24 weeks. Efficacy was assessed in the intention-to-treat population and safety was assessed in patients who received at least one dose of study medication. The trial was registered at ClinicalTrials.gov, NCT04998604.
FINDINGS: Between Sept 27, 2021, and Dec 27, 2024, 819 individuals were screened for study inclusion, 459 were excluded (most common screen failures were: 167 did not meet nasal polyp score ≥5 or did not have ongoing symptoms of nasal congestion and loss of smell, 114 did not meet pre-bronchodilator FEV1 ≤85% predicted normal, and 99 did not meet eligibility as per omalizumab drug-dosing), and 360 participants were randomly assigned (181 assigned to the dupilumab group and 179 assigned to the omalizumab group). Of the 360 participants, 198 (55%) participants were male, 162 (45%) were female, and the mean age of the total population sample was 52 years (SD 13·1). Improvements were significantly greater with dupilumab than omalizumab for all primary and secondary efficacy endpoints at week 24. Least squares mean differences in change from baseline dupilumab over omalizumab were: nasal polyp score -1·60 (95% CI -1·96 to -1·25; p<0·0001) and UPSIT 8·0 (6·3 to 9·7; p<0·0001). 115 (64%) of 179 participants in the dupilumab group and 116 (67%) of 173 participants in the omalizumab group reported treatment-emergent adverse events, the most common of which were nasopharyngitis, accidental overdose, headache, upper respiratory tract infection, and cough. There were no deaths in the study.
INTERPRETATION: Dupilumab was superior to omalizumab in patients with severe CRSwNP and coexisting asthma. These findings support the efficacy of dupilumab in patients with type 2 respiratory diseases versus an active biologic comparator, the known safety profiles of dupilumab and omalizumab, and could enable better treatment targeting for patients with CRSwNP and asthma in clinical practice.
FUNDING: Sanofi and Regeneron Pharmaceuticals.
参考来源
- De Corso E, Canonica GW, Heffler E, et al. Dupilumab versus omalizumab in patients with chronic rhinosinusitis with nasal polyps and coexisting asthma (EVEREST): a multicentre, randomised, double-blind, head-to-head phase 4 trial. Lancet Respir Med. 2025. PMID: 41033334. doi:10.1016/S2213-2600(25)00287-5
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。